Brenda Davenport
Nurse Practitioner · Aberdeen, SDNPI 1265560163
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 289 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,526, 2.5 times the $609 reported in 2021. Among nurse practitioner clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 289 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$910
- Teva Pharmaceuticals USA, Inc.$653
- Alkermes, Inc.$652
- Neurocrine Biosciences, Inc.$546
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$504
- Otsuka America Pharmaceutical, Inc.$336
- plus $920 from 14 others
What the payments were for
- Food & beverage$4,32796%
- Education$1944%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$4,521 in reported general payments places this provider in the 95th percentile of 504 nurse practitioner providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 25 | $339,162 |
| Invega SustennaPaliperidone Palmitate | 64 | $185,063 |
| IngrezzaValbenazine Tosylate | 13 | $100,967 |
| RexultiBrexpiprazole | 60 | $81,412 |
| Austedo XrDeutetrabenazine | 20 | $23,540 |
| NuedextaDextromethorphan Hbr/Quinidine | 15 | $22,672 |
| Clozapine | 162 | $12,476 |
| TrintellixVortioxetine Hydrobromide | 18 | $12,076 |
| Paliperidone ErPaliperidone | 92 | $11,412 |
| Duloxetine Hcl | 204 | $4,377 |
| ViibrydVilazodone Hcl | 12 | $3,553 |
| Olanzapine | 187 | $3,534 |
| Vilazodone Hcl | 60 | $3,410 |
| Divalproex Sodium ErDivalproex Sodium | 109 | $3,406 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 28 | $3,250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $653 | $362,70345 claims |
| Johnson & JohnsonInvega Sustenna | $156 | $185,06364 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $546 | $100,96713 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $336 | $81,41260 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $57 | $22,67215 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $45 | $12,07618 claims |
| AbbVieViibryd | $910 | $3,55312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 504 nurse practitioner providers in South Dakota.
Other nurse practitioner in Aberdeen
- Rosa EytonAberdeen$7K
- Jenny SchaefferAberdeen$3K
- Kalie NorbergAberdeen$2K
- Jamie BuschSioux Falls$60K
- Jessica SlabaSioux Falls$41K
- Christopher NelsonSioux Falls$35K
- Katherine EricsonSioux Falls$13K
- Kristi GlanzerHuron$6K
- Roger DeraadRapid City$6K
- Gabrielle PriceSioux Falls$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.